Sectors
Health, BioTech, AI
Headquarters
Cambridge, MA, USA
CEO
Jason Arunn Murugesu
Generate:Biomedicines shares, as of April 21, 2025, are valued at a price per share implying an approximate +19.41% relative to the most recent significant secondary market activity in December 2024, according to PM Insights' market data. PM Insights uses a market-driven derived price methodology to determine Generate:Biomedicines's valuation when recent secondary market transactions are limited or unavailable, as is currently the case for Generate:Biomedicines.
Register today to view the full report, with more in-depth details and analytics
Latest funding round
XXXXX
XX-XX-XXXX
AV Implied Valuation
XXXXX
XX-XX-XXXX
Change since Last Round
XXXXX
XX-XX-XXXX
Secondary Activity
XXXXX
Business Partnerships
Targeted Impact
Who Will Benefit?
What Comes Next?
No items found.
.png)
Generate:Biomedicines shares, as of April 21, 2025, are valued at a price per share implying an approximate +19.41% relative to the most recent significant secondary market activity in December 2024, according to PM Insights' market data. PM Insights uses a market-driven derived price methodology to determine Generate:Biomedicines's valuation when recent secondary market transactions are limited or unavailable, as is currently the case for Generate:Biomedicines.
Generate:Biomedicines's mutual fund disclosures indicate a three-month moving average fund price per share of $11.97 as of February 27, 2025, according to PM Insights' market data.
No items found.
No items found.
Ready to see it in action?
Schedule a demo with one of our experts
